Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17173253 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL9060595 | 0.74 | — | — | |
| SCHEMBL2737388 | 0.73 | — | — | |
| SCHEMBL7792046 | 0.70 | NPSR1 (0.53) | — | |
| SCHEMBL9734543 | 0.70 | ALPL (0.32) | — | |
| SCHEMBL24370740 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL12371612 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL22434652 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL19541992 | 0.70 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL22404379 | 0.69 | SMN1; SMN2 (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11326165-B1 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11162101-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11129829-B2 | Methods for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020163409-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-0312773-B1 | SUBSTITUTED 3-AMINOSYDNONIMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1991-12-27 | — | — | EP | disclosed |
| US-4937244-A | HYPOTENSIVE AND CARDIOTONIC AGENTS; ANGINA PECTORIS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1990-06-26 | — | — | US | disclosed |
| EP-0312773-A2 | Substituted 3-aminosydnonimines, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | SMN1; SMN2 317/4885 |
| US-11129829-B2 | Methods for modulating splicing | RBM17, SNRPE, SNRPB2 | SMN1; SMN2 145/4885 |
| US-11326165-B1 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | SMN1; SMN2 123/4885 |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | SMN1; SMN2 145/4885 |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | SMN1; SMN2 123/4885 |
| US-11162101-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SNRPA1 | SMN1; SMN2 123/4885 |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | SMN1; SMN2 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.